Newsfeed

Every published oncology item from an approved source, most recent first. No account required — this is the unfiltered stream, not personalized to any follows.

Items are tagged with the biomarkers and tumour types they resolve to; each tag opens that record, and every record’s page carries the same items back.

This demo serves a captured snapshot of the feed, not a live connection to the sources.

PubMed Central · Aug 27, 2026
Cell competition driven by secreted ligands: Modeling liver metastasis of colorectal cancer.
- colorectal cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 27, 2026
Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.
- pancreatic cancer (tumour type)
Read at PubMed Central
U.S. Food and Drug Administration · Aug 26, 2026
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
- pancreatic cancer (tumour type)
View original at U.S. Food and Drug Administration
PubMed Central · Aug 26, 2026
The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.
- pancreatic cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Early recurrence prediction after curative-intent surgery of intrahepatic cholangiocarcinoma using a novel weighted tumor burden score.
- Cholangiocarcinoma (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Current and future therapies for triple-negative breast cancer.
- breast cancer (tumour type)
- triple-negative breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.
- triple-negative breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
- non-small cell lung cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Nanomedicine strategies for overcoming multidrug resistance in breast cancer: recent advances and future perspectives.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.
- ovarian cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
PRS-BC(313) integration for tailored breast cancer prevention in female patients and their healthy relatives.
- breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.
- PD-L1 (biomarker)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming.
- pancreatic cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Efficacy of First-Line EGFR-TKI Treatment in Octogenarians with Lung Adenocarcinoma and Common EGFR Mutations.
- EGFR (biomarker)
Read at PubMed Central
PubMed Central · Aug 26, 2026
Pdcd4-Rictor interaction suppresses mTORC2-PFKFB3 axis and tumorigenesis in NSCLC.
- non-small cell lung cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 25, 2026
Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer.
- breast cancer (tumour type)
- triple-negative breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 25, 2026
MicroRNA profiles of prostate cancer bone metastases and miR-375 as an inhibitor of the aggressive metastasis subtype MetB.
- prostate cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 25, 2026
[Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].
- breast cancer (tumour type)
- triple-negative breast cancer (tumour type)
Read at PubMed Central
PubMed Central · Aug 25, 2026
Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.
- colorectal cancer (tumour type)
Read at PubMed Central

Newsfeed

Cell competition driven by secreted ligands: Modeling liver metastasis of colorectal cancer.

Intraoperative esketamine for postoperative analgesia and depression in pancreatic cancer surgery: protocol for a multicenter randomized controlled trial.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.

Early recurrence prediction after curative-intent surgery of intrahepatic cholangiocarcinoma using a novel weighted tumor burden score.

Current and future therapies for triple-negative breast cancer.

Heterogeneous treatment response in metastatic breast cancer: discordance between FDG-PET and CT classification.

RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.

AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.

Nanomedicine strategies for overcoming multidrug resistance in breast cancer: recent advances and future perspectives.

Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.

PRS-BC(313) integration for tailored breast cancer prevention in female patients and their healthy relatives.

Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.

Myoferlin at the crossroad of vesicle trafficking and mitochondrial function: implications for pancreatic cancer progression and stromal reprogramming.

Efficacy of First-Line EGFR-TKI Treatment in Octogenarians with Lung Adenocarcinoma and Common EGFR Mutations.

Pdcd4-Rictor interaction suppresses mTORC2-PFKFB3 axis and tumorigenesis in NSCLC.

Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer.

MicroRNA profiles of prostate cancer bone metastases and miR-375 as an inhibitor of the aggressive metastasis subtype MetB.

[Preparation of HLYVSPW peptide-displaying outer membrane vesicles and validation of their in vitro targeting effects on triple-negative breast cancer cells].

Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.